Myriad Genetics, Inc. (NASDAQ:MYGN) was the target of a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 16,412,692 shares, a drop of 12.9% from the August 15th total of 18,843,047 shares. Currently, 24.4% of the company’s shares are short sold. Based on an average daily trading volume, of 970,644 shares, the short-interest ratio is presently 16.9 days.

MYGN has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price target for the company in a report on Monday, July 17th. J P Morgan Chase & Co restated an “underweight” rating and set a $16.00 price target on shares of Myriad Genetics in a report on Friday, June 30th. BidaskClub upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. Cowen and Company restated a “hold” rating and set a $25.00 price target on shares of Myriad Genetics in a report on Friday, July 14th. Finally, Piper Jaffray Companies restated a “hold” rating and set a $22.00 price target on shares of Myriad Genetics in a report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. Myriad Genetics presently has an average rating of “Hold” and a consensus price target of $21.22.

Shares of Myriad Genetics (MYGN) opened at 32.75 on Friday. Myriad Genetics has a 12-month low of $15.15 and a 12-month high of $33.42. The company has a 50-day moving average of $28.48 and a 200 day moving average of $23.12. The firm has a market cap of $2.24 billion, a P/E ratio of 102.66 and a beta of 0.26.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.26 by $0.04. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The firm had revenue of $200.50 million during the quarter, compared to analyst estimates of $193.71 million. During the same quarter in the prior year, the business posted $0.36 earnings per share. Myriad Genetics’s revenue for the quarter was up 7.5% compared to the same quarter last year. Equities research analysts anticipate that Myriad Genetics will post $1.02 earnings per share for the current fiscal year.

In other news, Director John T. Henderson sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $30.30, for a total transaction of $909,000.00. Following the completion of the sale, the director now owns 52,524 shares in the company, valued at approximately $1,591,477.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 6.20% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Arizona State Retirement System acquired a new position in Myriad Genetics during the first quarter worth approximately $682,000. Bank of New York Mellon Corp increased its position in Myriad Genetics by 131.2% during the first quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock worth $17,632,000 after purchasing an additional 521,146 shares during the last quarter. Frontier Capital Management Co. LLC increased its position in Myriad Genetics by 1.4% during the first quarter. Frontier Capital Management Co. LLC now owns 3,075,954 shares of the company’s stock worth $59,058,000 after purchasing an additional 41,432 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Myriad Genetics by 4.4% during the first quarter. Schwab Charles Investment Management Inc. now owns 698,450 shares of the company’s stock worth $13,411,000 after purchasing an additional 29,348 shares during the last quarter. Finally, Great West Life Assurance Co. Can increased its position in Myriad Genetics by 958.4% during the first quarter. Great West Life Assurance Co. Can now owns 97,514 shares of the company’s stock worth $1,870,000 after purchasing an additional 88,301 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: “Myriad Genetics, Inc. (MYGN) Short Interest Down 12.9% in August” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/15/myriad-genetics-inc-mygn-short-interest-down-12-9-in-august.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.